Cantrixil Final Phase 1 Data, page-5

Actually the market cap is up massively from this time last year you might want to look a little farther a field than yesterday.

given the MC is up around 400% from this time last year and that includes a couple of incremental raises from inflection point to inflection point

and now that we have a loaded bank balance and phase 3 paid for - and with heaps of data coming out we could over the next year increase SP by a few multiples again this time without a raise

it’s great to see the CR covered more than the cost of the trial by all reports...

”If GCAR simply covers the cost of the control patients, the cost of the study is, at least, halved, from USD40m to USD20m, in my opinion.

It could be cut further given Kazia is likely to be the only second company to put its drug into the study.

To stay on the conservative side, however, I will stick with an estimate of USD20 million.

That estimate looks pretty good since management said Kazia will end up raising a little over AUD25 million in a recent rights issue, before fees. “

exciting times ahead - phase 3 trial substantially covered -money in the bank - 3 readouts to come this year and a major readout of trial data averaging each quarter over the next few years.